Rite Aid Pharmacy

riteaid.com

Rite Aid Corporation is one of the nation's leading drugstore chains with more than 4,900 stores in 31 states and the District of Columbia, with a strong presence on both the East and West coasts, and 109,000 associates.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NOVAVAX AIMS FOR BILLIONS COVID VACCINE DOSES COULD BE AVAILABLE BY END OF 2021

fiercepharma | August 12, 2020

news image

Some of the world’s largest biopharma companies are working to deliver safe and effective COVID-19 vaccines, but at the same time, a much smaller biotech has laid out its own big ambitions in the field. Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives say. On a conference call Monday, chief medical officer Filip Dubovsky said the Gaithersburg, MD-based biotech expects to be able to make "well over a coupl...

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

XERIS PHARMACEUTICALS ANNOUNCES USFDA APPROVAL OF RECORLEV

Xeris Pharmaceuticals, Inc. | January 31, 2023

news image

On January 30, 2023, Xeris Biopharma Holdings, Inc., a leading biopharmaceutical company, announced that the Food and Drug Administration (FDA) granted orphan-drug exclusivity (ODE) to its subsidiary Xeris Pharmaceuticals, Inc. for Recorlev® (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome in adult patients for whom surgery is not viable or has not been effective. levoketoconazole (Recorlev) being the first FDA-approved...

Read More

BUSINESS INSIGHTS

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

news image

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More

PHARMACY MARKET

SUNOVION AND OTSUKA INITIATE PHASE 3 CLINICAL DEVELOPMENT OF NON-RACEMIC AMISULPRIDE FOR THE TREATMENT OF PEOPLE WITH BIPOLAR DEPRESSION

Sunovion Pharmaceuticals Inc. | February 10, 2022

news image

Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development And Commercialization, Inc. announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Non-racemic amisulpride is being jointly developed and commercialized as part of a collaboration between Sunovion, its parent company Sumitomo Dainippon Pharma and Otsuka P...

Read More
news image

NOVAVAX AIMS FOR BILLIONS COVID VACCINE DOSES COULD BE AVAILABLE BY END OF 2021

fiercepharma | August 12, 2020

Some of the world’s largest biopharma companies are working to deliver safe and effective COVID-19 vaccines, but at the same time, a much smaller biotech has laid out its own big ambitions in the field. Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives say. On a conference call Monday, chief medical officer Filip Dubovsky said the Gaithersburg, MD-based biotech expects to be able to make "well over a coupl...

Read More
news image

BUSINESS INSIGHTS, PHARMACY MARKET

XERIS PHARMACEUTICALS ANNOUNCES USFDA APPROVAL OF RECORLEV

Xeris Pharmaceuticals, Inc. | January 31, 2023

On January 30, 2023, Xeris Biopharma Holdings, Inc., a leading biopharmaceutical company, announced that the Food and Drug Administration (FDA) granted orphan-drug exclusivity (ODE) to its subsidiary Xeris Pharmaceuticals, Inc. for Recorlev® (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome in adult patients for whom surgery is not viable or has not been effective. levoketoconazole (Recorlev) being the first FDA-approved...

Read More
news image

BUSINESS INSIGHTS

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More
news image

PHARMACY MARKET

SUNOVION AND OTSUKA INITIATE PHASE 3 CLINICAL DEVELOPMENT OF NON-RACEMIC AMISULPRIDE FOR THE TREATMENT OF PEOPLE WITH BIPOLAR DEPRESSION

Sunovion Pharmaceuticals Inc. | February 10, 2022

Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development And Commercialization, Inc. announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Non-racemic amisulpride is being jointly developed and commercialized as part of a collaboration between Sunovion, its parent company Sumitomo Dainippon Pharma and Otsuka P...

Read More